rifabutin
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberculosis
Conditions
Tuberculosis, Non-tuberculous Mycobacterial Diseases (Including MAC Disease)
Trial Timeline
Nov 1, 2008 → Jul 1, 2016
NCT ID
NCT00810407About rifabutin
rifabutin is a pre-clinical stage product being developed by Pfizer for Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00810407. Target conditions include Tuberculosis, Non-tuberculous Mycobacterial Diseases (Including MAC Disease).
What happened to similar drugs?
3 of 5 similar drugs in Tuberculosis were approved
Approved (3) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00810446 | Pre-clinical | Completed |
| NCT00810407 | Pre-clinical | Completed |
| NCT03164291 | Phase 3 | Completed |
Competing Products
20 competing products in Tuberculosis